Braze (NASDAQ:BRZE) delivered a strong close to fiscal 2026, and six Wall Street analysts responded with updated price targets that reflect genuine confidence in the company’s growth trajectory, tempered by valuation discipline in a compressed multiple environment. The stock had traded as high as $43.89 over the past 52 weeks before gaining more than 20% on March 25 in the wake of its earnings call. That makes the analyst target range of $30 to $40 a significant implied recovery.
| Firm | Analyst | Rating | Old Target | New Target |
|---|---|---|---|---|
| Barclays | Raimo Lenschow | Overweight | $29 | $31 |
| BTIG | N/A | Buy | $25 | $30 |
| Canaccord | David Hynes | Buy | $43 | $40 |
| Goldman Sachs | N/A | Buy | $45 | $40 |
| Mizuho | Siti Panigrahi | Outperform | $50 | $40 |
| Stifel | J. Parker Lane | Buy | $40 | $35 |
What Drove the Quarter
Braze reported Q4 revenue of $205.2 million, beating the consensus estimate of $198.23 million by 3.50% and marking 27.9% year-over-year growth. That acceleration is the story: revenue growth has climbed from 19.6% to 23.8% to 25.5% to 27.9% over four consecutive quarters. Quarterly bookings surged over 50% year-over-year, and the enterprise customer count, those spending $500K or more in annual recurring revenue, grew 34.8%. Remaining performance obligations crossed $1 billion for the first time.
The Analyst Divide
Barclays raised its target to $31 from $29, with analyst Raimo Lenschow pointing to three consecutive quarters of improved dollar-based net retention and organic revenue acceleration as catalysts for renewed investor interest. BTIG lifted its target to $30 from $25, citing the magnitude of upside in Braze’s FY2027 growth outlook and the robust bookings that sent the stock up roughly 20% in after-hours trading following the report.
Three firms trimmed targets despite maintaining bullish ratings. Canaccord’s David Hynes cut to $40 from $43, noting that initial FY2027 guidance calls for 20% growth and roughly 400 basis points of margin expansion, well ahead of the Street’s prior 16% growth estimate. Goldman Sachs reduced its target to $40 from $45 but kept Braze among its top picks, arguing the company can sustain accelerated share gains as legacy competitors struggle to deliver on AI promises. Mizuho’s Siti Panigrahi moved to $40 from $50, citing multiple contraction across the software sector while calling Braze’s AI momentum “promising.” Stifel’s J. Parker Lane trimmed to $35 from $40, noting Braze “closed the year on a high note” but reflecting sector-wide multiple compression.
What to Watch
The tension between accelerating fundamentals and a compressed valuation environment defines Braze’s current setup. Dollar-based net retention slipped to 109% from 111% year-over-year, and GAAP gross margin narrowed to 65.5% from 69.3%.
FY2027 full-year revenue guidance of $884 million to $889 million and non-GAAP EPS of $0.61 to $0.65 will be the benchmarks analysts track to determine whether target resets reflect a floor or a ceiling.
The pace of BrazeAI product adoption, particularly the Agent Console and Operator tools that launched ahead of schedule in February, will be a key signal in the quarters ahead.